Other News

Shore Capital-Backed IZI Medical Products Announces Acquisition of Quick-Core® Biopsy and Breast Localization Needle Assets from Cook Medical

CHICAGO–(BUSINESS WIRE)–IZI Medical Products, LLC (“IZI”), a leading interventional radiology medical device company and portfolio company of Shore Capital Partners, LLC (“Shore”), is pleased to announce it has acquired select soft tissue biopsy and breast localization needle assets from Cook Medical (“Cook”). The acquired portfolio of products are commercially marketed […]

Euphrates Vascular announces FDA clearance of the ICHOR Reperfusion System 

St. Louis, Missouri – Euphrates Vascular (www.euphratesvascular.com), a company focused on the treatment of vascular occlusions, recently received 510(k) clearance for sale of its ICHOR Percutaneous Reperfusion System. ICHOR is a Percutaneous Reperfusion System designed to treat organized thrombus and embolic events in the peripheral vasculature. ICHOR is a “one size fits […]

Intact Vascular Announces Presentations at LINC 2019 Annual Meeting

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured at the annual Leipzig Interventional Course (LINC) in Leipzig, Germany on Tuesday, January 22nd and Wednesday, January 23rd. Intact Vascular’s Tack Endovascular […]

Microbot Medical Increases its Global IP Portfolio with Notice of Allowance from the European Patent Office

HINGHAM, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) — Microbot Medical Inc. (NASDAQ: MBOT), received a notification from the European Patent Office that it will grant a patent for Application No. 08738207, which covers the Company’s ViRob™ technology platform. Including this latest notification, the Company has 30 issued/allowed patents and 18 […]

InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa

TEL AVIV, Israel, Jan. 14, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard EPS will be distributed by its local distribution partner, […]

Hercules Capital Provides US$15M From Existing Facility for Mesoblast to Accelerate Product Commercialization Programs

NEW YORK and MELBOURNE, Australia, Jan. 14, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit facility with Hercules Capital, Inc. (NYSE:HTGC). The funds will be used primarily to ramp up […]

FDA Approves World’s First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)

ABBOTT PARK, Ill., Jan. 14, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo™ Occluder, the world’s first medical device that can be implanted in the tiniest babies (weighing as little as two pounds) using a minimally invasive procedure to treat patent ductus arteriosus, or […]

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy

SANTA CLARA, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study – DISRUPT CAD III – for the […]

Endologix Appoints John D. Zehren as Chief Commercial Officer

IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that it has appointed John D. Zehren as the Company’s Chief Commercial Officer, effective as of January 7, 2019 (the “Effective Date”). Mr. Zehren brings to Endologix more than […]

Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

BEDMINSTER, N.J., Jan. 10, 2019 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer […]